Literature DB >> 34059604

New targets in inflammatory bowel disease therapy: 2021.

Nathaniel A Cohen1, David T Rubin.   

Abstract

PURPOSE OF REVIEW: In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD). RECENT
FINDINGS: Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies.
SUMMARY: The IBD physicians' therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34059604      PMCID: PMC8544288          DOI: 10.1097/MOG.0000000000000740

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   2.741


  46 in total

1.  Anti-adhesion molecule therapy for inflammatory bowel disease.

Authors:  Subrata Ghosh; Remo Panaccione
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

Authors:  Kim A Papp; Andrew Blauvelt; Michael Bukhalo; Melinda Gooderham; James G Krueger; Jean-Philippe Lacour; Alan Menter; Sandra Philipp; Howard Sofen; Stephen Tyring; Beate R Berner; Sudha Visvanathan; Chandrasena Pamulapati; Nathan Bennett; Mary Flack; Paul Scholl; Steven J Padula
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

Review 3.  Update on Janus kinase antagonists in inflammatory bowel disease.

Authors:  Brigid S Boland; William J Sandborn; John T Chang
Journal:  Gastroenterol Clin North Am       Date:  2014-06-24       Impact factor: 3.806

Review 4.  The microbiome in inflammatory bowel disease: current status and the future ahead.

Authors:  Aleksandar D Kostic; Ramnik J Xavier; Dirk Gevers
Journal:  Gastroenterology       Date:  2014-02-19       Impact factor: 22.682

5.  IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.

Authors:  David Yen; Jeanne Cheung; Heleen Scheerens; Frédérique Poulet; Terrill McClanahan; Brent McKenzie; Melanie A Kleinschek; Alex Owyang; Jeanine Mattson; Wendy Blumenschein; Erin Murphy; Manjiri Sathe; Daniel J Cua; Robert A Kastelein; Donna Rennick
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Authors:  W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

7.  Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.

Authors:  Geert R D'Haens; Walter Reinisch; Scott D Lee; Dino Tarabar; Edouard Louis; Maria Kłopocka; Jochen Klaus; Stefan Schreiber; Dong Il Park; Xavier Hébuterne; Peter Nagy; Fabio Cataldi; Steven W Martin; Satyaprakash Nayak; Anindita Banerjee; Kenneth J Gorelick; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2022-07-01       Impact factor: 7.290

8.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Authors:  Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

Review 9.  Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility.

Authors:  Franco Scaldaferri; Viviana Gerardi; Loris Riccardo Lopetuso; Fabio Del Zompo; Francesca Mangiola; Ivo Boškoski; Giovanni Bruno; Valentina Petito; Lucrezia Laterza; Giovanni Cammarota; Eleonora Gaetani; Alessandro Sgambato; Antonio Gasbarrini
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

Review 10.  Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Authors:  Siddharth Singh; John George; Brigid S Boland; Niels Vande Casteele; William J Sandborn
Journal:  J Crohns Colitis       Date:  2018-05-25       Impact factor: 9.071

View more
  4 in total

1.  Null Function of Npr1 Disturbs Immune Response in Colonic Inflammation During Early Postnatal Stage.

Authors:  Changkun Long; Hongfei Liu; Wenxing Zhan; Liping Chen; Andong Wu; Lin Yang; Shenghan Chen
Journal:  Inflammation       Date:  2022-07-07       Impact factor: 4.092

2.  Association between ulcerative colitis and Helicobacter pylori infection: A case-control study.

Authors:  Iyad Ali; Qusay Abdo; Shayma'a M Al-Hihi; Ansam Shawabkeh
Journal:  Heliyon       Date:  2022-02-09

3.  Tumor Necrosis Factor-α Induces a Preeclamptic-like Phenotype in Placental Villi via Sphingosine Kinase 1 Activation.

Authors:  Yuliya Fakhr; Saloni Koshti; Yasaman Bahojb Habibyan; Kirsten Webster; Denise G Hemmings
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

4.  Targeting CRAC channels in inflammatory bowel disease.

Authors:  Sven Kappel; Christine Peinelt
Journal:  EMBO Mol Med       Date:  2022-08-15       Impact factor: 14.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.